Live feed16:30:00·8dPRReleasevia QuantisnowCellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALLByQuantisnow·Wall Street's wire, on your screen.CLLS· Cellectis S.A.Health Care
